Clinical Trial Detail

NCT ID NCT01691898
Title A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Obinutuzumab + Pinatuzumab Vedotin + Rituximab

Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab

Obinutuzumab + Polatuzumab vedotin-piiq

Age Groups: senior adult

No variant requirements are available.